Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N′-Bis(2- chloroethyl)-N-nitrosurea in camptothecin-resistant cells

Molecular Pharmacology

Volumn 74, Issue 2, 2008, Pages 517-526

  Ma, Li Chen ^a,b   Kuo, Ching Chuan ^a   Liu, Jin Fen ^a   Chen, Li Tzong ^a   Chang, Jang Yang ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CARMUSTINE; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ADA PROTEIN, E COLI; ESCHERICHIA COLI PROTEIN; GROWTH INHIBITOR; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CELL STRAIN KB; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; DRUG SENSITIVITY; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; RNA STABILITY; CELL STRAIN HT29; COMPARATIVE STUDY; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CAMPTOTHECIN; CARMUSTINE; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GROWTH INHIBITORS; HT29 CELLS; HUMANS; KB CELLS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSCRIPTION FACTORS;

EID: 47949089043     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.043620     Document Type: Article

References (50)

1. Beidler DR, Chang JY, Zhou BS, and Cheng YC (1996) Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56:345-353.
2. 6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci U S A 82:2985-2989.
3. Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, and Friedman HS (2000) Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol 45:345-349.
4. Champoux JJ (1976) Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci U S A 73:3488-3491.
5. 6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res 52:1804-1809.
6. Chang JY, Dethlefsen LA, Barley LR, Zhou BS, and Cheng YC (1992) Characterization of camptothecin-resistant chinese hamster lung cells. Biochem Pharmacol 43:2443-2452.
7. Chang JY, Liu JF, Juang SH, Liu TW, and Chen LT (2002) Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res 62:3716-3721.
8. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
9. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, and Friedman HS (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41:485-490.
10. Day RS III, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM, and Bynum GD (1980) Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288:724-727.
11. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51:3367-3372.
12. Eng WK, Faucette L, Johnson RK, and Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760.
13. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797.
14. Feinberg AP and Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143-153.
15. Finlay GJ, Baguley BC, and Wilson WR (1984) A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 139:272-277.
16. Friedman HS, Keir ST, and Houghton PJ (2003) The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 97:2359-2362.
17. Fujimori A, Gupta M, Hoki Y, and Pommier Y (1996) Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 50:1472-1478.
18. Fuks F, Hurd PJ, Deplus R, and Kouzarides T (2003a) The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31:2305-2312.
19. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, and Kouzarides T (2003b) The methylCpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278:4035-4040.
20. Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, and Hansen JC (2003) Chromatin compaction by human MeCP2. assembly of novel secondary chromatin structures in the absence of DNA methylation. J Biol Chem 278:32181-32188.
21. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56:4430-4437.
22. Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA Jr, and Goodfellow PJ (1999) A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog 24:90-98.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, and Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
24. Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
25. Hsiang YH and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726.
26. Kaufmann WK, Boyer JC, Estabrooks LL, and Wilson SJ (1991) Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol 11:3711-3718.
27. 6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res 57:5360-5368.
28. 6-methylguanine DNA methyltransferase (MGMT) expression in Mer+ human tumor cells. Carcinogenesis 16:2255-2257.
29. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, and Chang JY (2004) BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 64:4621-4628.
30. 6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther 316:946-954.
31. Larsen AK and Skladanowski A (1998) Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1400:257-274.
32. Lee MP, Brown SD, Chen A, and Hsieh TS (1993) DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci USA 90:6656-6660.
33. Litt MD, Simpson M, Recillas-Targa F, Prioleau MN, and Felsenfeld G (2001) Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J 20:2224-2235.
34. Nan X, Campoy FJ, and Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471-481.
35. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, and Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389.
36. 6- methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93:93-102.
37. Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, and Futscher BW (2003) Mutant P53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22:3624-3634.
38. Park SY, Lam W, and Cheng YC (2002) X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62:459-465.
39. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119-6129.
40. Peters AH and Schubeler D (2005) Methylation of histones: playing memory with DNA. Curr Opin Cell Biol 17:230-238.
41. Shiraishi A, Sakumi K, and Sekiguchi M (2000) Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 21:1879-1883.
42. 6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35:1328-1334.
43. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, and Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962-7965.
44. 6- methylguanine-DNA methyltrans-ferase associated with resistance to alkylating drugs in a mammalian cell line. J Biol Chem 272:13250-13254.
45. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, and Pommier Y (2001) Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 61:1964-1969.
46. Wade PA (2001) Methyl CpG-binding proteins and transcriptional repression. Bioessays 23:1131-1137.
47. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
48. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619.
49. Zhang Y and Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343-2360.
50. Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S, Matsukura S, Matsuo S, Joh K, and Mukai T (2005) The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem (Tokyo) 137:431-440.